T

Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119

Watchlist Manager
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Watchlist
Price: 18.48 CNY -3.25% Market Closed
Market Cap: 8.6B CNY
Have any thoughts about
Tianjin Ringpu Bio-Technology Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Tianjin Ringpu Bio-Technology Co Ltd stock under the Base Case scenario is 30.14 CNY. Compared to the current market price of 18.48 CNY, Tianjin Ringpu Bio-Technology Co Ltd is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
30.14 CNY
Undervaluation 39%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

3.6
P/S
P/S
Price to Sales
3.6
vs History
77
vs Industry
42
Median 3Y
4
Median 5Y
4.2
Industry
2.5
Forward
3.1
More Details
20.3
P/E
P/E
Price to Earnings
20.3
vs History
69
vs Industry
32
Median 3Y
21.7
Median 5Y
23.4
Industry
21.8
Forward
18.1
More Details
16
P/OCF
P/OCF
Price to OCF
16
vs History
82
vs Industry
29
Median 3Y
21
Median 5Y
21
Industry
16.1
More Details
9.8
P/FCFE
P/FCFE
Price to FCFE
9.8
vs History
85
vs Industry
23
Median 3Y
36
Median 5Y
36.5
Industry
23.8
More Details
1.9
P/B
P/B
Price to Book Value
1.9
vs History
71
vs Industry
51
Median 3Y
2
Median 5Y
2.3
Industry
2.1
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
71
vs Industry
45
Median 3Y
3.7
Median 5Y
4.1
Industry
2.7
Forward
3
More Details
7.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.3
vs History
66
vs Industry
42
Median 3Y
7.6
Median 5Y
8.1
Industry
5.2
More Details
20.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.7
vs History
58
vs Industry
27
Median 3Y
20.3
Median 5Y
22.2
Industry
13.5
Forward
13
More Details
20.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
20.7
vs History
58
vs Industry
31
Median 3Y
20.3
Median 5Y
22.2
Industry
16.8
Forward
17
More Details
15.6
EV/OCF
EV/OCF
Enterprise Value to OCF
15.6
vs History
77
vs Industry
32
Median 3Y
18.9
Median 5Y
19.3
Industry
15.2
More Details
25.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
25.6
vs History
85
vs Industry
16
Median 3Y
50.7
Median 5Y
51.1
Industry
19.3
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
79
vs Industry
51
Median 3Y
1.8
Median 5Y
2.1
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Tianjin Ringpu Bio-Technology Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
8.6B CNY 3.6 20.3 20.7 20.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
743.6B USD 18.2 88.8 47.8 53.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
346B USD 3.9 23.6 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
248.8B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.5 169.4 253.9
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.9 9.4 13.2
US
Pfizer Inc
NYSE:PFE
149.2B USD 2.5 35.1 10.5 15.8
P/E Multiple
Earnings Growth P/E to Growth
CN
T
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Average P/E: 30.8
20.3
47%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
88.8
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.6
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.5
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.9
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
T
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Average EV/EBITDA: 415.6
20.7
125%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.4
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.4
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
T
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Average EV/EBIT: 1 812.1
20.7
111%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.8
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.9
131%
1.9
CH
Novartis AG
SIX:NOVN
13.2
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.